explore -WSS

explore

author：focus 2025-09-29 21:27:35 - browse：8271

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Hearing on Medicare drug price negotiation gets unusually heated

focus

leisure time

WSS

Second xenotransplant done with gene

Latest bird flu infection made farmworker sicker than earlier cases

CDC advisers recommend seasonal use of Pfizer RSV shot

Prosthetic arm enables patients to feel the objects they grip

Second xenotransplant done with gene

CDC advisers recommend seasonal use of Pfizer RSV shot

leisure time

explore

focus

The cancer drug shortage isn’t new — and neither are the solutions

Biotech lab space demand falls sharply

Moonlake's readout produced a cash windfall. Risks remain

Antibiotic resistance nearly killed me, so I'm raising awareness of it

DIEP, the 'gold standard' of breast reconstruction, is under threat

Report: NIH

Alkermes shareholders re

Report: NIH

Medical records are filled with copy

Changes to biosimilar regulatory framework must prioritize patients

hotspot

Dark money group runs ads on China biotech bill

Heat waves linked to early deliveries, preterm births in new study

CDC's new outbreak response network to include Northeastern

Changes to biosimilar regulatory framework must prioritize patients

STAT Virtual Event: Putting AI to the Test

Adam's Biotech Scorecard: Do Sarepta's exon

leisure time

focus

Wikipedia

hotspot